AAO 2020: Study confirms Phase III results for uveitis treatment

Conference|AAO

Glenn J. Jaffe, MD, presents a summary of the results of a confirmatory study on a previous Phase III trial that examined sustained drug delivery for the treatment of uveitis, as well as data on the 36-month results in the second, confirmatory phase 3 study of YUTIQ.

Glenn J. Jaffe, MD, presents a summary of the results of a confirmatory study on a previous Phase III trial that examined sustained drug delivery for the treatment of uveitis, as well as data on the 36-month results in the second, confirmatory phase 3 study of YUTIQ.

Related Videos
TENAYA, LUCERNE year 2 data reveals promising results for faricimab
How to diagnose geographic atrophy earlier
World Sight Day 2022: Eye care professionals share what global vision means to them
Related Content

Study: Cones in retinal degeneration, believed to be dormant, may retain visual function

March 28th 2023

Integrating AI to manage DR in a primary care setting

December 1st 2020

COPHy 2023: Weighing the merits of offering teprotumumab for all patients with thyroid eye disease

March 25th 2023

What to expect from virtual AAO 2020

November 5th 2020

Suprachoroidal TA for macular edema caused by noninfectious uveitis

March 19th 2023

COPHy 2023 sets stage for evidence-based debates and discussions

March 15th 2023

Study: Cones in retinal degeneration, believed to be dormant, may retain visual function

March 28th 2023

Integrating AI to manage DR in a primary care setting

December 1st 2020

COPHy 2023: Weighing the merits of offering teprotumumab for all patients with thyroid eye disease

March 25th 2023

What to expect from virtual AAO 2020

November 5th 2020

Suprachoroidal TA for macular edema caused by noninfectious uveitis

March 19th 2023

COPHy 2023 sets stage for evidence-based debates and discussions

March 15th 2023

Study: Cones in retinal degeneration, believed to be dormant, may retain visual function

March 28th 2023

Integrating AI to manage DR in a primary care setting

December 1st 2020

COPHy 2023: Weighing the merits of offering teprotumumab for all patients with thyroid eye disease

March 25th 2023

What to expect from virtual AAO 2020

November 5th 2020

Suprachoroidal TA for macular edema caused by noninfectious uveitis

March 19th 2023

COPHy 2023 sets stage for evidence-based debates and discussions

March 15th 2023
© 2023 MJH Life Sciences

All rights reserved.